NUVB logo

Nuvation Bio Inc. Class A (NUVB)

$3.90

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NUVB

Market cap

$1.38B

EPS

-0.4

P/E ratio

--

Price to sales

10.33

Dividend yield

--

Beta

1.73226

Price on NUVB

Previous close

$3.84

Today's open

$3.80

Day's range

$3.79 - $3.98

52 week range

$3.79 - $9.75

Profile about NUVB

CEO

David Hung

Employees

305

Headquarters

New York, NY

Exchange

New York Stock Exchange

Shares outstanding

353017638

Issue type

Common Stock

NUVB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NUVB

Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting

With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was 81.5% in patients with Grade 2 IDH1-mutant glioma Patients achieved a median target lesion reduction of 27.2% Topline long-term follow-up results were previously announced in July 2026 NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced new long-term follow-up data from the Phase 2 (J201) study of investigational safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma. The data, presented at the Society for Neuro-Oncology (SNO) 31st Annual Meeting in Philadelphia, demonstrated durable responses after longer follow-up, with a manageable safety profile.

news source

PRNewsWire • Nov 16, 2026

news preview

Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 2:30 p.m.

news source

PRNewsWire • Nov 10, 2026

news preview

Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients

Nuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million, even with new starts flat at about 160. With $663.4 million in cash, NUVB's management believes the company is funded through profitability.

news source

Seeking Alpha • Nov 9, 2026

news preview

What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call

Nuvation Bio NYSE: NUVB reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient starts declined across the broader ROS1 treatment market.

news source

MarketBeat • Nov 8, 2026

news preview

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both first-line and all lines of therapy combined, based on IQVIA claims data FDA approved a supplemental New Drug Application (sNDA) for IBTROZI, updating label to reflect median duration of response of 49.7 months in TKI-naïve ROS1+ NSCLC patients in TRUST-I FDA granted Fast Track Designation to safusidenib for the treatment of IDH1-mutant glioma Cash, cash equivalents, and marketable securities of $663.4 million as of September 30, 2026 Company to host a conference call today at 4:30 p.m. ET NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

news source

PRNewsWire • Nov 4, 2026

news preview

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.16 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting

Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase 2 results to be presented at SNO includes additional data beyond topline results previously announced in July 2026 NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three posters on ongoing studies of safusidenib, its selective investigational inhibitor of mutant IDH1, will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 12–15, 2026, in Philadelphia, PA. Positive topline Phase 2 J201 results were announced in July; additional key data will be featured in the SNO poster.

news source

PRNewsWire • Nov 2, 2026

news preview

Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries

New sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519) study of investigational safusidenib will expand to include study sites in the United Kingdom, France, Sweden, Germany, Italy and Spain. These additional countries extend SIGMA's global footprint beyond the U.S., Australia, China, Canada and Japan, where the study is currently enrolling or will soon begin enrolling.

news source

PRNewsWire • Oct 29, 2026

news preview

Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2026.

news source

PRNewsWire • Oct 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Nuvation Bio Inc. Class A

Open an M1 investment account to buy and sell Nuvation Bio Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NUVB on M1